Roots Analysis has done a detailed study on “Cell and Gene Therapy CROs Market, 2022-2035”, covering key aspects of the industry’s evolution and identifying potential future growth opportunities.
Key Market Insights
§ More than 105 CROs claim to provide a wide range of preclinical and clinical services for the development of advanced therapy medicinal products.
§ The current market landscape features the presence of established and emerging players, majority of the service providers offer research and analytical services for both cell and gene therapies at different scales of operation.
§ Around 1,330 cell and gene therapy focused clinical trials have been registered across the globe; most of the trials are focused on evaluating therapy candidates for the treatment of various oncological indications
§ In pursuit of a competitive edge and to eventually establish themselves as one-stop shops, stakeholders have actively entered into mutually beneficial partnerships
§ We expect industry stakeholders to continue to forge strategic alliances with niche / specialized players engaged in this domain to further augment their respective product offerings
§ Our proprietary analysis highlights several potential acquisition partners for cell and gene therapy service providers across different geographies
§ Our proprietary total cost of ownership model provides an informed estimate of direct and indirect expenses for setting up a contract research facility in different regions, over a span of 20 years
§ The market is expected to grow at a CAGR of over 21% in the coming decade; the opportunity is likely to be well distributed across areas of expertise, therapeutic areas, scales of operation and key geographical regions
Table of Contents
1. PREFACE
1.1. Scope of the Report
1.2. Market Segmentation
1.3. Research Methodology
1.4. Key Questions Answered
1.5. Chapter Outlines
2. EXECUTIVE SUMMARY
2.1. Chapter Overview
3. INTRODUCTION
3.1. Chapter Overview
3.2. Overview of Contract Research Organizations (CROs)
3.3. Type of Services Offered by CROs
3.4. Classification of CROs
3.5. Role of CROs in Development of Advanced Therapy Medicinal Products (ATMPs)
3.6. Advantages of Outsourcing Operations to CROs
3.7. Risks Associated with Outsourcing to CROs
3.8. Future Perspectives
4. GUIDE TO OUTSOURCING
4.1. Chapter Overview
4.2. Outsourcing Cell and Gene Therapy Research
4.3. Guiding Models of Outsourcing
4.4. Selecting an Appropriate Outsourcing Model
4.5. Selecting a CRO Partner
4.6. Role of CROs in Drug Development
4.7. Concluding Remarks
5. MARKET LANDSCAPE
5.1. Chapter Overview
5.2. Cell and Gene Therapy CROs: Overall Market Landscape
6. COMPANY PROFILES
6.1. Chapter Overview
6.2. Players based in North America
6.2.1. Altasciences
6.2.1.1. Company Overview
6.2.1.2. Service Portfolio
6.2.1.3. Recent Developments and Future Outlook
6.2.2. Allucent (Formerly Known as CATO SMS)
6.2.3. Charles River Laboratories
6.2.4. Creative Biolabs
6.2.5. IQVIA
6.2.6. Medpace
6.2.7. PPD
6.2.8. Precision for Medicine
6.2.9. QPS
6.3. Players based in Europe
6.3.2. Evotec
6.3.3. ICON
6.3.4. Syneos Health
6.4. Players based in Asia-Pacific
6.4.1. CMIC Group
6.4.2. Labcorp
7. COMPETITIVE BENCHMARKING
7.1. Chapter Overview
7.2. Assumptions and Key Methodology
7.3. Competitive Benchmarking by Region
7.4. Concluding Remarks
8. PARTNERSHIPS AND COLLABORATIONS
8.1. Chapter Overview
8.2. Partnership Models
8.3. Cell and Gene Therapy CROs: Partnerships and Collaborations
9. MERGERS AND ACQUISITIONS
9.1. Chapter Overview
9.2. Merger and Acquisition Models
9.3. Cell and Gene Therapy CROs: Mergers and Acquisitions
10. KEY ACQUISITION TARGETS
10.1. Chapter Overview
10.2. Scoring Criteria and Key Assumptions
10.3. Scope and Methodology
10.4. Potential Strategic Acquisition Targets Amongst Small Players
10.5. Potential Strategic Acquisition Targets Amongst Mid-sized Players
11. LIKELY PARTNER ANALYSIS FOR CELL THERAPY CROs
11.1. Chapter Overview
11.2. Scoring Criteria and Key Assumptions
11.3. Scope and Methodology
11.4. Key Potential Strategic Partners for Cell Therapy CROs
12. LIKELY PARTNER ANALYSIS FOR GENE THERAPY CROs
12.1. Chapter Overview
12.2. Scoring Criteria and Key Assumptions
12.3. Scope and Methodology
12.4. Key Potential Strategic Partners for Gene Therapy CROs
13. CLINICAL TRIAL ANALYSIS
13.1. Chapter Overview
13.2. Scope and Methodology
13.3. Cell Therapies: Analysis by Number of Clinical Trials
13.4. Cell Therapies: Analysis by Enrolled Patient Population
13.5. Gene Therapies: Analysis by Number of Clinical Trials
13.6. Gene Therapies: Analysis by Enrolled Patient Population
14. TOTAL COST OF OWNERSHIP FOR CELL AND GENE THERAPY CONTRACT RESEARCH ORGANIZATIONS
14.1 Chapter Overview
14.2. Key Parameters
14.3. Assumptions and Methodology
14.4 Sample dataset for the estimation of total cost of ownership
15. MARKET FORECAST AND OPPORTUNITY ANALYSIS
15.1. Chapter Overview
15.2. Key Assumptions and Methodology
15.3. Global Cell and Gene Therapy CROs Market, 2022-2035
16. SWOT ANALYSIS
16.1. Chapter Overview
16.2. Strengths
16.3. Weaknesses
16.4. Opportunities
16.5. Threats
16.6. Comparison of SWOT Factors
17. CONCLUSION
17.1. Chapter Overview
18. INTERVIEW AND SURVEY TRANSCRIPTS
18.1. Chapter Overview
18.2. CATO SMS
18.3. Changhai Hospital, Second Military Medical University
18.4. University of Colorado
16. APPENDIX 1: TABULATED DATA
17. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS
To view more details on this report, click on the link:
https://www.rootsanalysis.com/reports/view_document/cell-and-gene-therapy-cros-market/230.html
Learn from experts: do you know about these emerging industry trends?
Key Trends in Non-Viral Transfection Market
Deep Learning-based Interoperability: Advanced Neural Networks Mimicking the Human Brain
Learn from our recently published whitepaper: -
Next Generation Biomanufacturing – The Upcoming Era of Digital Transformation
About Roots Analysis
Roots Analysis is a global leader in the pharma / biotech market research. Having worked with over 750 clients worldwide, including Fortune 500 companies, start-ups, academia, venture capitalists and strategic investors for more than a decade, we offer a highly analytical / data-driven perspective to a network of over 450,000 senior industry stakeholders looking for credible market insights.
Learn more about Roots Analysis consulting services:
Roots Analysis Consulting - the preferred research partner for global firms
Contact:
Ben Johnson
+1 (415) 800 3415
English
Arabic
French
Portuguese
Deutsch
Turkish
Dutch
Italiano
Russian
Romaian
Portuguese (Brazil)
Greek